

Raptor Pharmaceutical Corp
Form 3
October 03, 2014

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Hyperion Trading Segregated Portfolio

(Last) (First) (Middle)

C/O TMF LTD. GRAND
PAVILLION COMM.
CTR, 2ND FL., 802 WEST
BAY ROAD, PO BOX 10338

(Street)

GRAND
CAYMAN, KY1-1003

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)
05/03/2012

3. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [RPTP]

4. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer ____ Other
(give title below) (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Common Stock, par value \$0.001 per share ⁽¹⁾ 4,885,587

D A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 4)

2. Date Exercisable and Expiration Date

3. Title and Amount of Securities Underlying

4. Conversion

5. Ownership

6. Nature of Indirect Beneficial Ownership

Edgar Filing: Raptor Pharmaceutical Corp - Form 3

(Month/Day/Year)		Derivative Security (Instr. 4)		Amount or Number of Shares	or Exercise Price of Derivative Security	Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)
Date Exercisable	Expiration Date	Title					
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	2,000	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	3,000	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	3,500	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	3,500	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	7,900	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	7,900	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	7,500	\$ 6.21 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	6,236	\$ 6.22 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	6,024	\$ 6.22 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	4,378	\$ 6.22 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	2,378	\$ 6.23 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	2,290	\$ 6.37 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	4,000	\$ 6.4 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	4,000	\$ 6.4 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	6,500	\$ 6.4 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	5,500	\$ 6.4 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	7,000	\$ 6.42 <u>(2)</u>	D	Â
Contracts for Difference <u>(2)</u>	Â <u>(2)</u>	Â <u>(2)</u>	Common Stock	2,500	\$ 4.55 <u>(2)</u>	D	Â

Edgar Filing: Raptor Pharmaceutical Corp - Form 3

Contracts for Difference (2)	Â (2)	Â (2)	Common Stock	1,200	\$ 4.41 (2)	D	Â
Contracts for Difference (2)	Â (2)	Â (2)	Common Stock	1,200	\$ 4.41 (2)	D	Â
Contracts for Difference (2)	Â (2)	Â (2)	Common Stock	2,000	\$ 4.41 (2)	D	Â
Contracts for Difference (2)	Â (2)	Â (2)	Common Stock	2,000	\$ 4.79 (2)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hyperion Trading Segregated Portfolio C/O TMF LTD. GRAND PAVILLION COMM. CTR 2ND FL., 802 WEST BAY ROAD, PO BOX 10338 GRAND CAYMAN,Â E9Â KY1-1003	Â	Â X	Â	Â

Signatures

/s/ David P.M. Blair and Richard A. Reinert 08/19/2014

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The shares of common stock, \$0.001 par value per share (the "Common Shares"), of Raptor Pharmaceutical Corp., a Delaware corporation, reported herein were held by Hyperion Trading Segregated Portfolio (the "Reporting Person"), a segregated portfolio of Strategic Investment Tribes Fund SPC, a Cayman Islands exempted company registered as a segregated portfolio company, managed by Star Arrow Funds Expertise Ltd, a company organized under the laws of Anguilla ("Star").

(2) On May 3, 2012, the Reporting Person held Contracts for Difference of the Common Shares (the "CFDs") reported herein with a securities broker (the "Issuer of the CFDs"), upon which, pursuant to an agreement between the Reporting Person and the Issuer of the CFDs, upon conversion of the CFDs (i) the Issuer of the CFDs would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion or, (ii) in the case that the purchase price of the CFDs (represented in column 4 of Table II) is less than the market price of the Common Shares at the time of conversion, the Reporting Person would be required to pay the difference between the purchase price of the CFDs (represented in column 4 of Table II) and the market price of the Common Shares at the time of conversion. As of May 3, 2012, the Reporting Person and the Issuer of the CFDs had not converted any of the CFDs.

Â

Remarks:

TheÂ CommonÂ SharesÂ andÂ CFDsÂ reportedÂ hereinÂ representÂ securitiesÂ (theÂ "Securities")Â heldÂ byÂ theÂ Rep

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.